The federal regulatory picture in plain English

Kratom occupies an unusual position in the US regulatory landscape. It is neither approved nor scheduled — neither blessed nor banned. The FDA says it does not meet the dietary supplement framework. The DEA has not added it to any Schedule. Federal agencies have advisories and import alerts but no enforceable nationwide prohibition. State legislatures, meanwhile, have moved aggressively over the past decade with the Kratom Consumer Protection Act framework — see our KCPA explainer — to fill the federal vacuum with consumer-safety rules.

To understand the present, the 2016 episode is the central event.

2016 — the DEA scheduling attempt and its withdrawal

On August 30, 2016, the DEA published a notice of intent to temporarily place mitragynine and 7-hydroxymitragynine into Schedule I — the most restrictive category, reserved for substances with no accepted medical use and high abuse potential. Schedule I placement would have made kratom federally illegal to produce, sell, possess, or import without DEA registration.

The reaction was unlike anything kratom had seen. The American Kratom Association coordinated a campaign that produced:

  • Over 130,000 public comments to the DEA — the largest comment volume on any DEA scheduling proposal at the time
  • A 142,000-signature White House petition
  • Congressional letters signed by more than 50 lawmakers across both parties asking the DEA to reconsider
  • National media coverage of veterans, chronic-pain patients, and former opioid users describing kratom's role in their lives

On October 12, 2016, the DEA formally withdrew the scheduling notice and announced it would defer to the FDA for further review. That deferral has held ever since. The DEA has not made a subsequent scheduling move on kratom in the decade since, and the FDA has not produced a binding action that would justify one.

What the FDA has done — and what it hasn't

The FDA's posture toward kratom has been consistently negative without producing a ban. Concrete actions over the past decade include:

  • Consumer advisories: Multiple statements warning consumers about kratom's risks, citing reports of dependence, withdrawal, and adverse events.
  • Import alerts: Authorization for FDA officials to detain imported kratom shipments without physical examination, allowing seizure at port of entry. Substantial volumes of imported kratom have been seized under these alerts.
  • Warning letters to manufacturers: Targeted letters to companies making unsubstantiated health claims (treating opioid withdrawal, anxiety, depression, etc.) — those claims are illegal for any unapproved product, kratom included.
  • Recalls: Coordination with manufacturers on voluntary recalls following contamination findings, most notably the 2018 multi-state Salmonella outbreak that sickened more than 200 people.
  • 2025 7-OH consumer alert: Specific targeting of concentrated synthetic 7-hydroxymitragynine products, citing dependence and overdose risk distinct from natural-leaf kratom. See our synthetic 7-OH explainer.

What the FDA has not done: scheduled kratom, banned its sale at retail, or successfully prosecuted a comprehensive case forcing the entire category off the market. The agency's position is that kratom is an unapproved drug; the practical reality is that the agency lacks the enforcement tools to remove it from US commerce without DEA scheduling or new legislation, neither of which has happened.

The DEA in 2026

The DEA's silence since 2016 is itself meaningful. After the public pushback to their scheduling notice, the agency has not signaled new interest. Internal DEA priorities have moved heavily toward fentanyl and methamphetamine enforcement, and kratom — without a clear public health crisis attributable to it — does not appear to be a current priority.

That doesn't mean the federal door is closed permanently. New scheduling action is possible if circumstances change — a major public health incident, sustained FDA recommendation, or political pressure from a new administration could re-open the question. As of 2026, none of those conditions are clearly present.

How state KCPA legislation fills the vacuum

With federal regulation absent and inconsistent, the actual rules consumers operate under are state-level. The Kratom Consumer Protection Act framework, championed by the American Kratom Association, has been adopted in more than a dozen states with active legislation in many more. KCPA-style laws typically establish:

  • 21+ age restriction for purchase
  • Mandatory truthful labeling of mitragynine and 7-OH content
  • Ban on synthetic alkaloids and 7-OH concentrates
  • Heavy-metal and microbial contamination thresholds
  • State-agency enforcement authority (typically Department of Agriculture or Health)

See our state-by-state legality guide for the current map.

What this means for consumers

The federal status of kratom is best understood as: tolerated but unblessed. You can legally buy and sell kratom in most US states, but the FDA's posture means:

  • No FDA-approved kratom products exist; any product claiming FDA approval is misrepresenting itself
  • No FDA-evaluated dosing recommendations exist; dose information comes from research, AKA guidelines, and vendor practice
  • Vendors cannot legally make health claims for kratom — companies that do are operating outside FDA/FTC rules and signaling broader carelessness about regulation
  • Quality and safety responsibility falls to the vendor and the consumer; this is why per-batch third-party COAs and AKA GMP qualification matter so much in this category

The likely 2026 trajectory

Three trend lines are stable enough to forecast through year-end:

  1. FDA continues advisory posture, not enforcement. More consumer alerts and warning letters, especially against synthetic 7-OH products. No DEA scheduling re-attempt absent a major triggering event.
  2. State-level KCPA adoption keeps growing. Several state legislatures have active KCPA bills. Federal stagnation makes the state framework increasingly important.
  3. The synthetic 7-OH market gets squeezed out. KCPA caps, FDA action, and industry pressure are aligning against this category. Natural- leaf kratom benefits from the cleanup.

The bottom line

Kratom is federally legal but federally unblessed. The FDA dislikes it, the DEA has stayed quiet since 2016, and the actual operational regulation is state-level KCPA legislation that mandates testing, labeling, and age restrictions. Consumers navigating this landscape should focus on what they can control: buying from AKA Qualified Vendors, reading per-batch COAs, and avoiding any product that either makes FDA-style health claims or sells concentrated 7-OH under the kratom label.